All Blogs
Nov 20, 2023
Phathom Secures Dual FDA Approvals for Voquezna Following Impurity Setback
Within a three-day period, Phathom Pharmaceuticals achieves dual FDA approvals for Voquezna, its groundbreaking heartburn medication. The first approval on 30 October involves the reformulation of Voquezna to address Helicobacter pylori infection, followed by a second approval on 01 November for treating gastroesop...
Read More...
Nov 29, 2024
The Next Chapter in NSCLC Treatment Space: Recent Discoveries and Innovations
Lung cancer was the most prevalent cancer globally, with 2.5 million new cases, representing 12.4% of all new cancer diagnoses. NSCLC is the most common type of lung cancer, accounting for over 85% of all cases. As per the latest estimates, the total incident cases of NSCLC in the 7MM were approximately 500K cases ...
Read More...
Nov 16, 2023
GE Healthcare and Masimo Announced Collaboration; Samsung Launched New Ultrasound System ‘V6’; MONARCH Platform Approved for Bronchoscopy in China; Lunit Received FDA Nod for Lunit INSIGHT DBT; Route 92 Medical Releases Tenzing Technology Clinical Findings; Vivasure Medical Enrolled 100th Patient for its Vivasure PerQseal Closure Device System Study
GE HealthCare and Masimo Collaborated on Patient Monitoring Tech On November 8, 2023, GE HealthCare and Masimo announced a joint agreement to integrate patient monitoring technologies. The goal of the partnership is to incorporate Masimo Signal Extraction Technology (SET) pulse oximetry into GE HealthCa...
Read More...
Nov 15, 2023
Evaluating the Growing Role of Rehabilitation Equipment in Revitalizing Lives and Improving the Treatment Outcome
Rehabilitation equipment, a cornerstone in the realm of healthcare, has undergone a remarkable evolution over the years, propelled by the rising demand and their potential to improve patient outcomes and restore quality of life. From rudimentary tools and manual therapies to the present-day sophisticated, technolog...
Read More...
Nov 14, 2023
Takeda’s ADZYNMA Approved by FDA; AskBio Presents Preliminary Data from Phase I Trial of Gene Therapy for CHF; Bayer’s Aflibercept 8 mg Recommended for Approval in EU; FDA Orphan Drug Designation to MAIA Biotechnology’s THIO; First Patient Dosed in Phase III ProstACT GLOBAL Study; FDA Grants Orphan Designation for Lipella’s LP-310 Drug Candidate
Takeda’s ADZYNMA Approved by FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura Takeda has received FDA approval for ADZYNMA (ADAMTS13, recombinant-krhn) for both prophylactic and on-demand treatment in adults and pediatri...
Read More...
Nov 10, 2023
Roche’s Vabysmo Third US Approval Spiced Up the Battle With Regeneron and Bayer’s Eylea
Roche’s Vabysmo secures a new FDA nod for retinal vein occlusion treatment, intensifying the competition with Regeneron and Bayer’s Eylea in the eye medication market. This approval for Vabysmo in RVO adds another shared medical indication for the competing eye medications. Vabysmo’s successful FDA approval for RVO...
Read More...
Nov 13, 2023
Servier’s Tibsovo Opens The Door To A New Era In The Battle Against Myelodysplastic Syndromes
Servier’s Tibsovo (ivosidenib tablets) has received an expanded indication from the FDA, allowing its utilization in patients diagnosed with relapsed or refractory myelodysplastic syndromes that exhibit an IDH1 mutation. This new approval represents the fifth for Tibsovo, which is already recognized for its efficac...
Read More...
Nov 09, 2023
SIBIONICS’s Ground-breaking GS1 Continuous Glucose Monitoring System; Abbott’s HPV Test to Run on Alinity m; CleanNA’s CE-IVD Molecular Diagnostics Product; Orthofix’s WaveForm L Interbody System; Alucent Biomedical’s AlucentNVS Technology; Surmodics’s TRANSCEND Trial Data
SIBIONICS Received CE Mark for Its Ground-breaking GS1 Continuous Glucose Monitoring System On November 01, 2023, SIBIONICS, the world's third-largest Continuous Glucose Monitoring System (CGM) brand, received the CE Mark for its revolutionary GS1 CGM. This significant milestone marks a momentous achiev...
Read More...
Nov 08, 2023
Glowing Prospects: Energy-Based Aesthetic Devices Market Outlook
The Energy-Based Aesthetic Devices market stands at the forefront of the evolving landscape of cosmetic treatments, offering a comprehensive range of solutions for individuals seeking non-invasive and minimally invasive procedures to enhance their appearance. Over the past few years, intense advancements in technol...
Read More...
Nov 07, 2023
New Asundexian Phase III Study Result; Zibotentan/Dapagliflozin Combination Demonstrated Significant Albuminuria Reduction Chronic Kidney Disease; Orphan Drug Designation to Rhenium Obisbemeda; FDA Approves Merck’s KEYTRUDA Plus Gemcitabine and Cisplatin for Biliary Tract Cancer; Orphan Drug Designation to Ayala’s AL102; GARDP Announces Successful Phase 3 Trial of of Uncomplicated Gonorrhea
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea The Global Antibiotic Research & Development Partnership (GARDP), in partnership with Innoviva, Inc. (Nasdaq: INVA), had announced a significant milestone. They revealed that zolif...
Read More...